Shirish M Gadgeel

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. ncbi Biochemotherapy of melanoma
    Lawrence E Flaherty
    Department of Internal Medicine, Division of Hematology and Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA
    Semin Oncol 29:446-55. 2002
  2. ncbi Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer
    Shirish M Gadgeel
    Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Clin Lung Cancer 13:96-106. 2012
  3. ncbi Crizotinib: an anaplastic lymphoma kinase inhibitor
    Shirish M Gadgeel
    Karmanos Cancer Institute, Experimental Therapeutics Program, Wayne State University, 4100 John R, Detroit, MI 48201, USA
    Future Oncol 7:947-53. 2011
  4. ncbi Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor
    Shirish M Gadgeel
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Cancer 110:2775-84. 2007
  5. ncbi Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)
    Shirish M Gadgeel
    Karmanos Cancer Institute Wayne State University, Detroit, Michigan, USA
    J Thorac Oncol 2:299-305. 2007
  6. ncbi Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines
    Shirish M Gadgeel
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Cancer 115:2165-76. 2009
  7. ncbi Patterns of care in a population-based sample of soft tissue sarcoma patients in the United States
    Shirish M Gadgeel
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Cancer 115:2744-54. 2009
  8. ncbi Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer
    Shirish M Gadgeel
    Thoracic Oncology Program, Karmanos Cancer Institute Wayne State University, Detroit, Michigan, USA
    J Thorac Oncol 6:927-33. 2011
  9. ncbi Novel combinations using pemetrexed in malignant mesothelioma
    Shirish M Gadgeel
    Wayne State University Karmanos Cancer Institute, Detroit, MI 48201, USA
    Clin Lung Cancer 5:S61-6. 2004
  10. ncbi The optimal chemotherapy for stage III non-small cell lung cancer patients
    Shirish M Gadgeel
    4100 John R, 4 HWCRC, Detroit, MI 48201, USA
    Curr Oncol Rep 13:272-9. 2011

Detail Information

Publications31

  1. ncbi Biochemotherapy of melanoma
    Lawrence E Flaherty
    Department of Internal Medicine, Division of Hematology and Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA
    Semin Oncol 29:446-55. 2002
    ..Many other issues regarding biochemotherapy, such as sequence, outpatient administration, and use in the adjuvant setting, for stage III melanoma are being actively evaluated...
  2. ncbi Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer
    Shirish M Gadgeel
    Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Clin Lung Cancer 13:96-106. 2012
    ....
  3. ncbi Crizotinib: an anaplastic lymphoma kinase inhibitor
    Shirish M Gadgeel
    Karmanos Cancer Institute, Experimental Therapeutics Program, Wayne State University, 4100 John R, Detroit, MI 48201, USA
    Future Oncol 7:947-53. 2011
    ..Preliminary data suggest that the drug may also be active in tumors with an activated c-Met pathway...
  4. ncbi Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor
    Shirish M Gadgeel
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Cancer 110:2775-84. 2007
    ..Therefore, it was hypothesized that tumor EGFR mutation status may influence the effectiveness of simultaneous EGFR and COX-2 inhibition in patients with NSCLC...
  5. ncbi Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)
    Shirish M Gadgeel
    Karmanos Cancer Institute Wayne State University, Detroit, Michigan, USA
    J Thorac Oncol 2:299-305. 2007
    ....
  6. ncbi Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines
    Shirish M Gadgeel
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Cancer 115:2165-76. 2009
    ..The authors hypothesized that genistein, through the inhibition of NF-kappaB, could enhance the activity of EGFR-TKIs in NSCLCs...
  7. ncbi Patterns of care in a population-based sample of soft tissue sarcoma patients in the United States
    Shirish M Gadgeel
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Cancer 115:2744-54. 2009
    ..The authors conducted a detailed analysis of STS patients diagnosed in 2002 and sampled from the Surveillance, Epidemiology, and End Results registries...
  8. ncbi Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer
    Shirish M Gadgeel
    Thoracic Oncology Program, Karmanos Cancer Institute Wayne State University, Detroit, Michigan, USA
    J Thorac Oncol 6:927-33. 2011
    ..We conducted a phase II study to assess the efficacy and feasibility of integrating pemetrexed in a concurrent therapy plan for patients with stage III NSCLC...
  9. ncbi Novel combinations using pemetrexed in malignant mesothelioma
    Shirish M Gadgeel
    Wayne State University Karmanos Cancer Institute, Detroit, MI 48201, USA
    Clin Lung Cancer 5:S61-6. 2004
    ..This article summarizes the data regarding pemetrexed in the treatment of malignant mesothelioma and the potential novel combinations involving the drug that may be used in the future for the treatment of the disease...
  10. ncbi The optimal chemotherapy for stage III non-small cell lung cancer patients
    Shirish M Gadgeel
    4100 John R, 4 HWCRC, Detroit, MI 48201, USA
    Curr Oncol Rep 13:272-9. 2011
    ..Ongoing clinical trials are evaluating the utility of integrating some of the newer agents such as pemetrexed and cetuximab into the treatment plan for stage III patients...
  11. ncbi Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials
    Shirish M Gadgeel
    Karmanos Cancer Institute Wayne State University, Detroit, MI, USA
    Clin Lung Cancer 12:218-23. 2011
    ..We conducted an analysis of the Cancer Therapy Evaluation Program (CTEP)-sponsored phase I trials to assess the outcomes of lung cancer patients enrolled in phase I trials...
  12. ncbi Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer
    Shirish M Gadgeel
    Thoracic Oncology Program, Karmanos Cancer Institute Wayne State University, Detroit, Michigan, USA
    J Thorac Oncol 3:1293-300. 2008
    ..We conducted a phase II study to evaluate the efficacy of the combination of weekly docetaxel and celecoxib in advanced NSCLC patients, who were either elderly (> or =70 years) or PS2...
  13. ncbi Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy
    Bryan J Schneider
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, Michigan, USA
    J Thorac Oncol 3:1454-9. 2008
    ..To evaluate the efficacy and toxicity of the combination of celecoxib and docetaxel in patients with advanced non-small cell lung cancer after failure of platinum-based therapy...
  14. ncbi Retrospective review of cancer patients > or =80 years old treated with chemotherapy at a comprehensive cancer center
    Minsig Choi
    Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Crit Rev Oncol Hematol 67:268-72. 2008
    ..The percentage of cancer patients > or =80 years old is expected to increase in the next few years. However data on the use of chemotherapy in these patients are limited...
  15. ncbi Soy isoflavones radiosensitize lung cancer while mitigating normal tissue injury
    Gilda G Hillman
    Department of Radiation Oncology, Wayne State University School of Medicine, 4100 John R Road, Detroit, MI 48201, USA
    Radiother Oncol 101:329-36. 2011
    ..We have now investigated the combination of soy with RT in lung cancer (NSCLC), for which RT is limited by radiation-induced pneumonitis...
  16. ncbi Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, 525 East 68th Street, J 321, New York, NY 10021, USA
    Invest New Drugs 27:571-8. 2009
    ....
  17. ncbi Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York City, New York, USA
    J Thorac Oncol 6:1117-20. 2011
    ..The prognosis for patients with extensive-stage small cell lung cancer remains poor. This trial was designed to evaluate the efficacy and toxicity of maintenance sunitinib after platinum-etoposide chemotherapy...
  18. ncbi Treatment of lung cancer
    Shirish M Gadgeel
    Department of Hematology and Oncology, Wayne State University, Karmanos Cancer Institute, 4HWCRC, 4100 John R Street, Detroit, MI 48201, USA
    Radiol Clin North Am 50:961-74. 2012
    ..Advanced NSCLC remains an incurable disease. Further advances will rely on improvements in understanding of the molecular events driving the malignant phenotype and the development of novel, targeted therapeutic strategies...
  19. ncbi Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?
    Antoinette J Wozniak
    Karmanos Cancer Institute Wayne State University, Detroit, Michigan 48201, USA
    Oncology (Williston Park) 21:163-71; discussion 171, 174, 179-82. 2007
    ..Molecular markers such as ERCC1 may determine response to treatment. All of these innovations will hopefully increase cure rates for lung cancer patients by maximizing the efficacy of adjuvant therapy...
  20. ncbi Parameters for individualizing systemic therapy in non-small cell lung cancer
    Shirish M Gadgeel
    Department of Oncology, Wayne State University, MI 48201, USA
    Drug Resist Updat 13:196-204. 2010
    ..Future development will lead to increasing complexity in clinical decision making with substantial anticipated benefits to patients including increased therapeutic efficacy, reduced toxicity, and better quality of life...
  21. ncbi Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, 4100 John R, Mail Code HW04HO, Detroit, MI 48201, USA
    Invest New Drugs 26:159-67. 2008
    ..This Phase I clinical study was conducted to evaluate the dose and administration schedule of ZD6126...
  22. ncbi Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer
    Shirish M Gadgeel
    Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute and Wayne State University, Detroit, MI 48201, USA
    Am J Clin Oncol 26:37-41. 2003
    ..This regimen needs to be further evaluated in combination with other agents and as a component of multimodality therapy in gastric cancer...
  23. ncbi Racial differences in lung cancer
    Shirish M Gadgeel
    Department of Medicine, Wayne State University, Karmanos Cancer Institute, Detroit, MI, USA
    Cancer Metastasis Rev 22:39-46. 2003
    ..Further research is required to determine the factors responsible for these differences and to develop effective preventative and therapeutic interventions that will impact favorably on the incidence and prognosis of this disease...
  24. ncbi Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design
    Shirish M Gadgeel
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Clin Cancer Res 11:6233-9. 2005
    ..The accelerated titration "2B" design may help in determining MTD with fewer patients enrolled and more being treated closer to the MTD. However, the accelerated titration design did not seem to shorten the study duration...
  25. ncbi Soy isoflavones augment radiation effect by inhibiting APE1/Ref-1 DNA repair activity in non-small cell lung cancer
    Vinita Singh-Gupta
    Department of Radiation Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    J Thorac Oncol 6:688-98. 2011
    ..Soy isoflavones sensitize cancer cells to radiation both in vitro and in vivo. To improve the effect of radiotherapy for non-small cell lung cancer, we assessed the potential of using a complementary approach with soy isoflavones...
  26. ncbi Predictors of enrollment in lung cancer clinical trials
    Wei Du
    Department of Pediatrics, Wayne State University, Detroit, Michigan 48201, USA
    Cancer 106:420-5. 2006
    ..Only approximately 5% of patients with newly diagnosed cancer participate in clinical trials nationwide, and African-American (AA) patients are particularly under-represented...
  27. ncbi Erlotinib resistance in lung cancer: current progress and future perspectives
    Joy Tang
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine Detroit, MI, USA
    Front Pharmacol 4:15. 2013
    ..Better insight into the molecular mechanisms behind combination therapy pathways and even single molecular pathways may help improve the efficacy of the current treatment options...
  28. ncbi Modern staging of small cell lung cancer
    Gregory P Kalemkerian
    Division of Hematology Oncology, University of Michigan, Ann Arbor, Michigan 48109 5848, USA
    J Natl Compr Canc Netw 11:99-104. 2013
    ..Recent data suggest that PET can improve both staging accuracy and treatment planning in patients with SCLC, although further prospective studies are needed to fully define its role...
  29. ncbi Adjuvant therapy for resected non-small cell lung cancer
    Antoinette J Wozniak
    Professor of Medicine and Oncology, Karmanos Cancer Institute, 4 Hudson Webber, 4100 John R, Detroit, MI 48201, USA
    Ther Adv Med Oncol 1:109-18. 2009
    ..Molecular markers such as ERCC1 may determine response to treatment. Increasing the understanding of the molecular makeup of lung cancer will hopefully increase cure rates for patients by maximizing the efficacy of the adjuvant therapy...
  30. ncbi Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial
    George R Simon
    Thoracic Oncology Program and Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, MRC 4W, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    J Clin Oncol 26:3567-72. 2008
    ..This clinical study assessed safety and efficacy of pemetrexed plus gemcitabine in chemotherapy-naïve patients with MPeM...
  31. ncbi Smoking history: tumor biology and clinical pharmacokinetic implications in patients with lung cancer
    Shirish M Gadgeel
    Clin Lung Cancer 7:369-70. 2006